ASP6432 is a potent and specific lysophosphatidic acid receptor type 1 (LPA1) antagonist (inhibitor) with IC50s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively.

Physicochemical Properties

Molecular Formula	C26H32KN4O6S2
Molecular Weight	599.783784866333
Exact Mass	598.132
CAS #	1282549-08-9
PubChem CID	138454774
Appearance	Light yellow to yellow solid powder
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	13
Heavy Atom Count	39
Complexity	857
Defined Atom Stereocenter Count	0
SMILES	[K].S1C=C(C(NS(NCC)(=O)=O)=O)N=C1CN(C(C1C=C(C(C)=C(C=1)OC)OC)=O)CCCC1C=CC=CC=1
InChi Key	WKYBXXHNGOTYDD-UHFFFAOYSA-M
InChi Code	InChI=1S/C26H32N4O6S2.K/c1-5-27-38(33,34)29-25(31)21-17-37-24(28-21)16-30(13-9-12-19-10-7-6-8-11-19)26(32)20-14-22(35-3)18(2)23(15-20)36-4;/h6-8,10-11,14-15,17,27H,5,9,12-13,16H2,1-4H3,(H,29,31);/q;+1/p-1
Chemical Name	potassium;[2-[[(3,5-dimethoxy-4-methylbenzoyl)-(3-phenylpropyl)amino]methyl]-1,3-thiazole-4-carbonyl]-(ethylsulfamoyl)azanide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	LPA-induced proliferation of human prostate stromal cells is inhibited by ASP6432 [1].
References	[1]. Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation. J Pharmacol Exp Ther. 2018 Aug;366(2):390-396.

Solubility Data

Solubility (In Vitro)

DMSO : ~250 mg/mL (~417.52 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 4.17 mg/mL (6.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.17 mg/mL (6.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.6673 mL	8.3364 mL	16.6728 mL
	5 mM	0.3335 mL	1.6673 mL	3.3346 mL
	10 mM	0.1667 mL	0.8336 mL	1.6673 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.